View Future GrowthPsyence Group 과거 순이익 실적과거 기준 점검 0/6Psyence Group의 수입은 연평균 -11.5%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 30.5% 증가했습니다.핵심 정보-11.52%순이익 성장률4.23%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률-1,898.58%순이익률n/a최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.공지 • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.공지 • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.공지 • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.공지 • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.공지 • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.공지 • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.공지 • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.공지 • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.공지 • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.공지 • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.매출 및 비용 세부 내역Psyence Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:PSYG.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비30 Sep 250-123030 Jun 250-134131 Mar 25005031 Dec 240-285130 Sep 240-245130 Jun 240-264031 Mar 240-284231 Dec 230-53330 Sep 230-73330 Jun 230-74331 Mar 230-64231 Dec 220-44130 Sep 220-44030 Jun 220-54031 Mar 220-54031 Dec 210-155030 Sep 210-156030 Jun 210-1550양질의 수익: PSYG.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: PSYG.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PSYG.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 11.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PSYG.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PSYG.F은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PSYG.F는 현재 수익성이 없으므로 자본 수익률이 음수(-1898.58%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/07 19:03종가2025/11/10 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Psyence Group Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ryan HamptonHannam & Partners (Advisory) LLP
공지 • Dec 02Psyence Group Inc., Annual General Meeting, Jan 30, 2026Psyence Group Inc., Annual General Meeting, Jan 30, 2026.
공지 • Aug 23Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc.Psyence Group Inc. (CNSX:PSYG) signed a letter of intent to acquire Gold Coast Resources Inc on August 22, 2025. It is anticipated that the Acquisition will be completed by way of a three-corner amalgamation or similar transaction under the Business Corporations Act (Ontario), pursuant to which a wholly owned subsidiary of Psyence will amalgamate with Gold Coast Resources and each issued and outstanding common share of the Gold Coast Resources will be exchanged for one common share of the resulting issuer ("Resulting Issuer Share"). Convertible securities of the Gold Coast Resources will be exchanged on the same basis. The exchange ratio refers to post-consolidation shares of Psyence Group Inc., if applicable. Pursuant to the LOI, Psyence will advance a secured loan to GoldCoast bearing interest at 10% per annum, maturing on the earlier of the closing of the Acquisition and December 31, 2025, and secured against all assets of GoldCoast. The use of proceeds of the Loan will be for the preparation and submission of the application for the exploration license as well as the preparation of the NI 43-101 Qualified Persons report. The Acquisition is subject to execution of a definitive agreement, completion of satisfactory due diligence by each party, receipt of all required corporate, shareholder and regulatory approvals and other customary closing conditions. Following closing, the board of directors and senior management of the Resulting Issuer will be reconstituted to include nominees of Gold Coast Resources.
공지 • Jun 19Psyence Group Inc. announced that it expects to receive CAD 0.6 million in fundingPsyence Group Inc. announces a non-brokered private placement to issue 6,000,000 common shares at a price of CAD 0.10 per share for gross proceeds of CAD 600,000 on June 18, 2025. The Offering is expected to close on or about June 25, 2025, or such other date as the Company may determine, and is subject to certain conditions, including receipt of all necessary regulatory approvals. No finder’s fees or commissions will be payable in connection with the Offering. The Offering is expected to close on or about June 25, 2025.
공지 • Oct 15Psyence Group Inc., Annual General Meeting, Dec 16, 2024Psyence Group Inc., Annual General Meeting, Dec 16, 2024.
공지 • Apr 06Psyence Group Inc., Annual General Meeting, Jun 07, 2024Psyence Group Inc., Annual General Meeting, Jun 07, 2024.
공지 • Mar 27An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG).An undisclosed buyer entered into a conditional agreement to acquire Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) for CAD 1 million on March 11, 2024. The transaction is approved by the board and is subjected to certain closing conditions.An undisclosed buyer completed the acquisition of Mind Health (Pty) Ltd and Psyence Uk Group Ltd from Psyence Group Inc. (CNSX:PSYG) on March 26, 2024. Psyence is pleased that the conditions to implement the transaction have been met.
공지 • Nov 21Psyence Group Inc. Announces Resignation of Marvin Singer as Board MemberPsyence Group Inc. announced that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during his tenure.
공지 • Oct 31Psyence Group Inc. announced that it has received CAD 0.162697 million in fundingPsyence Group Inc. announced a private placement of 1,355,810 common shares at a price of CAD 0.12 per unit for the gross proceeds of CAD 162,697 on October 30, 2023. The transaction included participation from returning individual investors, Brandon Kerzner and Cody Futeran. As a part of the transaction, the company also issued 2,467 common shares at a price of CAD 0.12 per common share as payment of a finder's fee of CAD 296.
공지 • Jul 12Psyence Group Inc. Appoints Christopher Bull to Board of DirectorsPsyence Group Inc. announced the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. He is recognized for his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies and has received a number of international awards in recognition hereof.
공지 • Jan 25Psyence Group Inc. Appoints AC Braddock to Scientific Advisory BoardPsyence Group Inc. appointed AC Braddock, CEO of Eden Labs, to its Scientific Advisory Board to utilize her skill sets in methodology and product development.
공지 • Jan 24Psyence Group Inc., Annual General Meeting, Mar 09, 2023Psyence Group Inc., Annual General Meeting, Mar 09, 2023.